Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma

Annals of Surgical Oncology

Volumn 19, Issue 9, 2012, Pages 2908-2916

  Gaujoux, Sébastien ^a   Torres, Javiera ^a   Olson, Sara ^a   Winston, Corrine ^a   Gonen, Mithat ^a   Brennan, Murray F ^a   Klimstra, David S ^a   D'Angelica, Michael ^a   Dematteo, Ronald ^a   Fong, Yuman ^a   House, Michael ^a   Jarnagin, William ^a   Kurtz, Robert C ^a   Allen, Peter J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FATTY LIVER; FEMALE; FIBROSIS; HUMAN; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; OBESITY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BLOOD LOSS, SURGICAL; BODY FAT DISTRIBUTION; BODY MASS INDEX; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTRA-ABDOMINAL FAT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OBESITY; OPERATIVE TIME; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROPORTIONAL HAZARDS MODELS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 84867403420     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2301-y     Document Type: Article

References (42)

1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557-67.
2. Vital signs: state-specific obesity prevalence among adults-United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:951-5.
3. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med. 2003;348:1625-38.
4. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007;120:1993-8.
5. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4:579-91.
6. Genkinger JM, Spiegelman D, Anderson KE, et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129:1708-17.
7. White PB, True EM, Ziegler KM, et al. Insulin, leptin, and tumoral adipocytes promote murine pancreatic cancer growth. J Gastrointest Surg. 2010;14:1888-93.
8. Zyromski NJ, Mathur A, Pitt HA, et al. Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery. 2009;146:258-63.
9. Khasawneh J, Schulz MD, Walch A, et al. Inflammation and mitochondrial fatty acid beta-oxidation link obesity to early tumor promotion. Proc Natl Acad Sci U S A. 2009;106:3354-9.
10. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301:2553-62.
11. Fleming JB, Gonzalez RJ, Petzel MQ, et al. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg. 2009;144:216-21.
12. Balentine CJ, Enriquez J, Fisher W, et al. Intra-abdominal fat predicts survival in pancreatic cancer. J Gastrointest Surg. 2010;14:1832-7.
13. Khan S, Sclabas G, Reid-Lombardo K, et al. Does body mass index/morbid obesity influence outcome in patients who undergo pancreatoduodenectomy for pancreatic adenocarcinoma? J Gastrointest Surg. 2010;14:1820-5.
14. Olson SH, Chou JF, Ludwig E, et al. Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer. 2010;127:2412-9.
15. Tsai S, Choti MA, Assumpcao L, et al. Impact of obesity on perioperative outcomes and survival following pancreaticoduodenectomy for pancreatic cancer: a large single-institution study. J Gastrointest Surg. 2010;14:1143-50.
16. House MG, Fong Y, Arnaoutakis DJ, et al. Preoperative predictors for complications after pancreaticoduodenectomy: impact of BMI and body fat distribution. J Gastrointest Surg. 2008;12:270-8.
17. Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg. 2007;204:356-64.
18. Ammann RW, Heitz PU, Kloppel G. Course of alcoholic chronic pancreatitis: a prospective clinicomorphological long-term study. Gastroenterology. 1996;111:224-31.
19. Gaujoux S, Cortes A, Couvelard A, et al. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery. 2010;148:15-23.
20. Guiu B, Petit JM, Bonnetain F, et al. Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut. 2010;59:341-7.
21. Physical status: The use and the interpretation of anthropometry: Report of a WHO expert committee. World Health Organ Tech Rep Ser. 1995; (854): 1-452.
22. Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer. 2005;93:1310-5.
23. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (Pan-Scan). Arch Intern Med. 2010;170:791-802.
24. Kant P, Hull MA. Excess body weight and obesity-the link with gastrointestinal and hepatobiliary cancer. Nat Rev Gastroenterol Hepatol. 2011;8:224-38.
25. Ansary-Moghaddam A, Huxley R, Barzi F, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev. 2006;15:2435-40.
26. Berrington de Gonzalez A, Spencer EA, Bueno-de-Mesquita HB, et al. Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2006;15:879-85.
27. McWilliams RR, Matsumoto ME, Burch PA, et al. Obesity adversely affects survival in pancreatic cancer patients. Cancer. 2010;116:5054-62.
28. Benns M, Woodall C, Scoggins C, McMasters K, Martin R. The impact of obesity on outcomes following pancreatectomy for malignancy. Ann Surg Oncol. 2009;16:2565-9.
29. Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337-44.
30. Chaston TB, Dixon JB. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes (Lond). 2008;32:619-28.
31. Wirth A, Steinmetz B. Gender differences in changes in subcutaneous and intra-abdominal fat during weight reduction: an ultrasound study. Obes Res. 1998;6:393-9.
32. Kuk JL, Ross R. Influence of sex on total and regional fat loss in overweight and obese men and women. Int J Obes (Lond). 2009;33:629-34.
33. Abate N. Insulin resistance and obesity. The role of fat distribution pattern. Diabetes Care. 1996;19:292-4.
34. Demerath EW, Reed D, Rogers N, et al. Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am J Clin Nutr. 2008;88:1263-71.
35. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: The Framingham Heart Study. Circulation. 2007;116:1234-41.
36. Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: Association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39-48.
37. Weinsier RL, Hunter GR, Gower BA, Schutz Y, Darnell BE, Zuckerman PA. Body fat distribution in white and black women: Different patterns of intraabdominal and subcutaneous abdominal adipose tissue utilization with weight loss. Am J Clin Nutr. 2001;74:631-6.
38. Goodpaster BH. Measuring body fat distribution and content in humans. Curr Opin Clin Nutr Metab Care. 2002;5:481-7.
39. Mathur A, Zyromski NJ, Pitt HA, et al. Pancreatic steatosis promotes dissemination and lethality of pancreatic cancer. J Am Coll Surg. 2009;208:989-94.
40. Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A. Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas. 2011;40:931-7.
41. Mathur A, Hernandez J, Shaheen F, et al. Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. HPB (Oxford). 2011;13:404-10.
42. Ramsey AM, Martin RC. Body mass index and outcomes from pancreatic resection: a review and meta-analysis. J Gastrointest Surg. 2011;15:1633-42.